SSIEM 2023 infographic: AADC deficiency: Advances in diagnosis and treatment
This infographic, distributed at the PTC Therapeutics symposium at SSIEM 2023, gives an overview of the diagnosis and treatment of aromatic L-amino acid decarboxylase (AADC) deficiency
Learn more about AADC deficiency, a rare autosomal recessive disease
Review current and emerging approaches for identifying and diagnosing patients with AADC deficiency
Discover more about eladocagene exuparvovec, an intraputaminal gene therapy for AADC deficiency
Review the clinical safety and efficacy data of eladocagene exuparvovec
▼ Eladocagene exuparvovec is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC Therapeutics at firstname.lastname@example.org.
Eladocagene exuparvovec (UpstazaTM) is a gene therapy indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of AADC deficiency with a severe phenotype, currently licensed in the European Member States, Great Britain, Iceland, Liechtenstein, Northern Ireland and Norway.
Registration conditions differ internationally; always consult local prescribing information and/or Summary of Product Characteristics before prescribing any product.
This infographic was developed and funded by PTC Therapeutics for SSIEM 2023.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-AADC-2300227 | October 2023
Sign in or register to access exclusive content on this site